ABOS
Acumen Pharmaceuticals Inc
NASDAQ: ABOS · HEALTHCARE · BIOTECHNOLOGY
$2.34
-4.88% today
Updated 2026-04-29
Market cap
$169.01M
P/E ratio
—
P/S ratio
538.78x
EPS (TTM)
$-2.00
Dividend yield
—
52W range
$1 – $4
Volume
0.6M
Acumen Pharmaceuticals Inc (ABOS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.82M | $-7.45M | $-17.96M | $-35.15M | $-43.06M | $-86.22M | $-115.54M |
| Capital expenditures | $40000.00 | $40000.00 | $40000.00 | $161000.00 | $21000.00 | $16000.00 | $88000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $174000.00 | $154000.00 | $922000.00 | $3.06M | $6.14M | $9.63M | $9.85M |
| Free cash flow | $-6.86M | $-7.49M | $-18.00M | $-35.31M | $-43.09M | $-86.23M | $-115.63M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $0.00 | $0.00 | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $78.39M | $7.94M | — | — | — |